A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats

Huang, Juan; Garmise, Robert J.; Crowder, Timothy M.; Mar, Kevin D.; Hwang, C. Robin; Hickey, Anthony; Mikszta, John A.; Sullivan, Vincent J.

doi:10.1016/j.vaccine.2004.06.049

Cited by 93 publications

(69 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the position of the device in the trachea of the animal during powder delivery may affect the percentage of powder deposited in the different lung lobes [95]. [60,107] and gene therapy [108,68].…”

Section: Direct Administration Methodsmentioning

confidence: 99%

“…Hormonally and immunologically guinea pigs are more like humans than other rodents; thus they are often used to model human infectious diseases [58]. Although rats are not as similar to humans they have been used to study a range of diseases such as emphysema [59], influenza [60] and pulmonary fibrosis [61]. Other systemic diseases such as diabetes can be induced in rats by administration of streptozocin [62].…”

Section: Animal Modelsmentioning

confidence: 99%

See 1 more Smart Citation

In vivo animal models for drug delivery across the lung mucosal barrier☆

Cryan

Sivadas

García-Contreras

2007

Advanced Drug Delivery Reviews

130

View full text Add to dashboard Cite

Section: Direct Administration Methodsmentioning

confidence: 99%

Section: Animal Modelsmentioning

confidence: 99%

In vivo animal models for drug delivery across the lung mucosal barrier☆

Cryan

Sivadas

García-Contreras

2007

Advanced Drug Delivery Reviews

130

View full text Add to dashboard Cite

“…To our knowledge, this is the first time that sIgA responses following nasal vaccination with FMDV nanoparticles of whole inactivated virus have been reported, although induction of systemic and mucosal immune responses by nasal vaccination with whole inactivated influenza virus has been reported in rats. 34,57 Our results indicated that animals in Gr-2 immunized three times by intranasal route with Chi-Tre-Inactivated nanoparticles on days 1, 4, and 7 had IgA responses that were slightly higher than the group immunized once with two intranasal doses of Chi-Tre-Inactivated nanoparticles (Gr-3) on 7 dpv and 10 dpv. Induction of IgA responses after vaccination and possible protection against challenge with FMDV requires further research.…”

mentioning

confidence: 69%

“…Powder-formulated vaccine elicited a significant serum antibody response in rats that was at least as strong as the response from liquid vaccine administered by intranasal route or by intramuscular injection. 33,34 In these reports, a mouse model was used to assess vaccine efficacy mediated by nanoparticle delivery by intranasal delivery, against influenza virus, parainfluenza, hepatitis B, and Streptococcus pneumoniae pathogens.…”

mentioning

confidence: 99%

Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles

Pan¹,

Zhang²,

Lv³

et al. 2014

IJN

View full text Add to dashboard Cite

The aim of this study was to enhance specific mucosal, systemic, and cell-mediated immunity and to induce earlier onset of protection against direct-contact challenge in cattle by intranasal delivery of a nanoparticle-based nasal vaccine against type A foot-and-mouth disease (FMD). In this study, two kinds of nanoparticle-based nasal vaccines against type A FMD were designed: (1) chitosan-coated poly(lactic-co-glycolic acid) (PLGA) loaded with plasmid DNA (Chi-PLGA-DNA) and (2) chitosan-trehalose and inactivated foot-and-mouth disease virus (FMDV) (Chi-Tre-Inactivated). Cattle were immunized by an intranasal route with nanoparticles and then challenged for 48 hours by direct contact with two infected donor cattle per pen. Donors were inoculated intradermally in the tongue 48 hours before challenge, with 0.2 mL cattle-passaged FMDV. Serological and mucosal antibody responses were evaluated, and virus excretion and the number of contact infections were quantified. FMDV-specific secretory immunoglobulin (Ig)A (sIgA) antibodies in nasal washes were initially detected at 4 days postvaccination (dpv) with two kinds of nanoparticles. The highest levels of sIgA expression were observed in nasal washes, at 10 dpv, from animals with Chi-PLGA-DNA nanoparticles, followed by animals immunized once by intranasal route with a double dose of Chi-Tre-Inactivated nanoparticles and animals immunized by intranasal route three times with Chi-Tre-Inactivated nanoparticles ( P <0.05). FMDV-specific IgA antibodies in serum showed a similar pattern. All animals immunized by intranasal route developed low levels of detectable IgG in serum at 10 dpv. Following stimulation with FMDV, the highest levels of proliferation were observed in splenocytes harvested from Chi-PLGA-DNA-immunized animals, followed by proliferation of cells harvested from Chi-Tre-Inactivated nanoparticle-immunized animals ( P <0.05). Higher protection rates were associated with the highest sIgA antibody responses induced in the Chi-PLGA-DNA nanoparticle-immunized group. Only one animal was clinically affected with mild signs after 7 days of contact challenge, after a delay of 2–3 days compared with the clinically affected negative-control group. Of the five animals directly challenged that were vaccinated by intranasal route with a double dose of Chi-Tre-Inactivated, four were clinically infected; however, the degree of severity of disease in this group was lower than in control cattle. The number of viral RNA copies in nasal swabs from the vaccinated, severely infected group was significantly higher than in swabs from the vaccinated, clinically protected group. These data suggested that intranasal delivery of Chi-PLGA-DNA nanoparticles resulted in higher levels of mucosal, systemic, and cell-mediated immunity than did of Chi-Tre-Inactivated nanoparticles. In conclusion, although intranasal delivery with FMDV antigen mediated by nanoparticles did not provide complete clinical protection, it reduced disease severity and...

show abstract

“…Influenza vaccine liquid formulation can be stored frozen at −20°C for a year in the presence of sucrose and for at least twenty days at 4°C by addition of deuterium oxide (D 2 O) [40,41]. Lyophilized formulations of measles and influenza can usually be stored long term at higher temperatures, although they need to be used as soon as possible after reconstitution [42,43]. Non enveloped viruses such as adenoviruses and polioviruses can be stabilized for longer periods of time at high temperatures such as 37°C and 45°C [39,44,45].…”

Section: Discussionmentioning

confidence: 99%

The stability of human respiratory syncytial virus is enhanced by incorporation of the baculovirus GP64 protein

Sastre

Oomens

Wertz

2007

Vaccine

View full text Add to dashboard Cite

Current efforts to develop a vaccine against human respiratory syncytial virus (HRSV) are focused on live attenuated strains. However, the unstable nature of HRSV is a major challenge for the preparation, storage and distribution of live vaccine candidates. We report here that the stability of HRSV can be improved by incorporation of the GP64 glycoprotein from baculovirus Autographa californica multiple nucleopolyhedrovirus. GP64 was incorporated in place of or in addition to the homologous HRSV glycoproteins and was either expressed from the HRSV genome or provided by propagating the virus in a Vero cell line constitutively expressing GP64 (Vbac cells). The infectivity of the different virus stocks was monitored after storage at 4°C, 22°C or 37°C, over a period of 8 weeks. The results showed that the infectivity of HRSV could be stabilized by up to 10,000 fold by the GP64 protein, when stored at 22°C for six weeks. This approach for stabilizing live HRSV may be important for vaccine development and may also prove useful for stabilizing other enveloped viruses.

show abstract

A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats

Cited by 93 publications

References 34 publications

In vivo animal models for drug delivery across the lung mucosal barrier☆

In vivo animal models for drug delivery across the lung mucosal barrier☆

Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles

The stability of human respiratory syncytial virus is enhanced by incorporation of the baculovirus GP64 protein

Contact Info

Product

Resources

About